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Abstract
Background Incidence rates for adenocarcinoma of the
lung are increasing and are higher in the United States than
in many other developed countries. We examine whether
these trends may be associated with changes in cigarette
design.
Methods Lung cancer risk equations based on observa-
tions during 1960–1972 from the American Cancer Society
Cancer Prevention Study I are applied to 5-year birth
cohort–speciﬁc estimates of changes in smoking behaviors
to predict birth cohort–speciﬁc rates of squamous cell
carcinoma and adenocarcinoma of the lung among US
White men for the period 1973–2000. These expected rates
are compared to observed rates for the same birth cohorts
of White men in the US Surveillance, Epidemiology and
End Results (SEER) data.
Results Changes in smoking behaviors over the past
several decades adequately explain the changes in squa-
mous cell carcinoma rates observed in the SEER data.
However, predicted rates for adenocarcinoma do not match
the observed SEER data without inclusion of a term
increasing the risk for adenocarcinoma with the duration of
smoking after 1965.
Conclusion The risk of developing squamous cell carci-
noma from smoking appears to have remained stable in the
United States over the past several decades; however, the
risk of adenocarcinoma has increased substantially in a
pattern temporally associated with changes in cigarette
design.
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Introduction
Adenocarcinoma of the lung has increased in the United
States (US) over the past several decades both in terms of
absolute incidence rates and as a fraction of all lung can-
cers [1–4]. In addition, incidence rates of adenocarcinoma
of the lung in the United States are higher than those for
many other developed countries [2] even though smoking
prevalence rates are generally slightly lower in the United
States. Several potential explanations for this increase have
been examined and found not to explain the increase in
adenocarcinoma including changes in the availability of
diagnostic techniques such as bronchoscopy [5–7] and
changes in criteria for histological classiﬁcation [7].
The temporal association of this rise in adenocarcinoma
with changesin cigarette design, and differencesincigarette
design between the United States and some other countries
raisequestionsaboutthecontributionofchangesincigarette
design and resultant composition of the smoke to the shift in
thetypeoflungcancerfrompredominantlysquamouscellto
predominantly adenocarcinoma [4, 5, 8–10].
Two large prospective mortality studies of lung cancer
risk conducted by the American Cancer Society in the
United States two decades apart reveal an increase in
overall lung cancer risk among cigarette smokers from
the 1960s to the 1980s even when adjusted for duration
and intensity of cigarette smoking [5, 10]. The risk of
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cancer, also increased in smokers during the interval
between these two studies [5]. In contrast, overall lung
cancer risks for never smokers remain unchanged over time
[11, 12], and rates of adenocarcinoma among never
smokers were similar in the two studies [5].
Risk models derived from smoking behaviors and
overall lung cancer mortality rates during the 1960s sub-
stantially underestimate current US lung cancer mortality
rates ([13, 14] Burns et al., submitted). This underestimate
can be corrected by adjusting for the duration of smoking
after 1972 (Burns et al., submitted) suggesting that the
increase in risk may be related to changes in the charac-
teristics of the cigarettes smoked over time.
Rates of squamous cell carcinoma in Canada and
Australia are similar to those of White men in the United
States, but rates of adenocarcinoma are lower in Canada and
Australia [2]. US style blended cigarettes have higher levels
of tobacco-speciﬁc nitrosamines, organ-speciﬁc carcino-
gensforadenocarcinomaofthelunginanimals[15],andUS
smokers have higher levels of biomarkers of exposure for
tobacco-speciﬁc nitrosamines than smokers in Australia or
Canada [16]. In addition, most lower yield cigarettes have
ventilated ﬁlters that may lead to deeper inhalation and
increased deposition of smoke in the alveolar regions of the
lungs. These concerns are of particular importance as US
style blended cigarettes gain market share in many countries
where the WHO Framework Convention on Tobacco Con-
trol may create an opportunity to regulate these changes in
cigarette design and composition.
We hypothesize that the increase in adenocarcinoma of
the lung over time and differences between US adenocar-
cinoma rates and those of other countries may be due to
differences in cigarette design and composition over time
and across countries, and that the increase in the risk of
adenocarcinoma contributes to an increase in overall lung
cancer rates.
We examine whether smoking dose and duration-spe-
ciﬁc risk equations derived from the lung cancer mortality
rates experienced in CPS I during the 1960s predict
changes in US birth cohort–speciﬁc incidence of squamous
cell carcinoma and adenocarcinoma of the lung during
subsequent decades. We hypothesize that, if changes in the
characteristics of cigarettes smoked result in a new and
additional risk of adenocarcinoma, risk equations devel-
oped in the 1960s would continue to predict temporal
changes in birth cohort–speciﬁc incidence of squamous cell
lung cancer but would progressively underestimate birth
cohort–speciﬁc incidence of adenocarcinoma as calendar
year advanced. White men were selected for these analyses
because CPS I has substantially fewer lung cancer deaths
among women, or among African Americans, making the
development of risk equations for smoking behaviors in the
1960s for these groups less reliable and more difﬁcult to
interpret.
Methods
Lung cancer risk model
Published risk equations derived from the lung cancer
mortality experience of White men in the 12-year follow-up
(1960–1972) of CPS I with terms for age, duration of
smoking, and number of cigarettes smoked per day are used
toestimatelungcancerrisksforactivesmokers[17,18].The
form of these equations is as excess risk equations with
the risk being the sum of the risk for never smokers and the
excess risk produced by smoking (RS = RNS ? ERS). Age-
speciﬁc risks for never smokers are also derived from CPSI
data [17]. The parameters used for the never smokers risk
are RNS = (9.21 e
-13) * (age
4.6); and for the excess risk
in smokers, the parameters are ERS = (1.51 e
-13)*
(age
2.38) * (cpd
0.867) * (dur
2.87). Excess risk equations, also
based on CPS I data,and including a term for the duration of
abstinence from smoking, are used to estimate risks for
former smokers [17].
Birth cohort–speciﬁc estimates of smoking behavior
Estimates of smoking behaviors for White men in the US
population were developed in conjunction with the
National Cancer Institute Cancer Intervention and Sur-
veillance Modeling Network (CISNET) and are available
on the CISNET website. Using a dataset combining ques-
tions on smoking behavior from all of the National Health
Interview Surveys from 1965 to 2005 and methods
described elsewhere [19, 20], birth cohort–speciﬁc esti-
mates for each calendar year between 1972 and 2000 are
provided for rates of smoking initiation, prevalence of
current and former smoking, the distribution of the duration
of smoking for current and former smokers, the distribution
of number of cigarettes smoked per day for current and
former smokers, and the distribution of duration of absti-
nence for former smokers.
Observed and estimated lung cancer incidence rates
Incidence rates for cancer of the lung and bronchus among
White men were obtained from SEER data by single year
of age and by single calendar year from 1973 to 2003 using
SEER*Stat software from three registries—SEER 9, 13,
and 17. Lung cancer death rates for White men matching
the following criteria were obtained: no prior cancer,
conﬁrmation by autopsy or death certiﬁcate only, clinical
diagnosis only and in situ. They were categorized
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Cell (codes 8041–8045), Squamous (codes 8050–8089),
Adenocarcinoma (codes 8140–8149, 8160, 8161, 8162,
8190–8221, 8260–8337, 8350–8551, 8570–8576, 8940–
8941), and Large Cell (codes 8012–8014). Rates are gen-
erated by ﬁve-year birth cohorts for cohorts beginning with
1915–1919 and ending with 1950–1954 and for ages
40–75 years.
Birth cohort–speciﬁc estimates of lung cancer rates are
generated by applying the risk equations for never, current,
and former smokers to population estimates of smoking
behavior for each calendar year. Smoking behaviors are
arranged in cells speciﬁc for smoking status, duration of
smoking, duration of abstinence, and cigarettes smoked per
day; and lung cancer mortality rates are estimated for each
cell using the risk equations developed from CPS I. A
summary rate for the entire cohort in a given year is gen-
erated as the average (weighted by the fraction of the pop-
ulation in the cell) of the rates in all of the cells for that year.
These estimates of lung cancer rates are converted into
estimates for each histological type by multiplying the
estimated rates by the fraction of that histological type
recorded by the SEER registry during the years 1973–1975.
These proportions are 14.21% (n = 1,779) for small cell,
36.71% (n = 4,597) for squamous cell, 17.58% (n = 2201
for adenocarcinoma, 3.13% (n = 392) for large cell, and
28.38% (n = 3,554) for other. The result is type-speciﬁc
estimates of lung cancer incidence based on smoking risks
observed in the 1960s and type distributions from 1973 to
1975.
Adjustments to the estimates
Difference between the mortality in CPS I and US mortality
Lung cancer incidence for a healthy population such as that
in CPS I is expected to be lower than that for the general
US population [21]. Incidence rates are also higher than
mortality rates. We use a power function to adjust the
predicted mortality rates upward and ﬁt them to the esti-
mated birth cohort and calendar year–speciﬁc incidence
rates in the SEER data from 1973 to 2000. By ﬁtting the
predicted rates to the observed SEER rates using non-linear
regression, we derive parameters a, a constant, and c, the
exponent of the power function. For the incidence of
squamous cell lung cancer, the estimation equation
becomes:
LCSEER ¼ a   f½ðNS   LCNSÞþð CS   LCCSÞþð FS   LCFSÞ 
  SquamousPropg
c
where NS, CS and FS are the proportions of never, current
and former smokers in the birth cohort in a speciﬁed
calendar year, and LCNS,L C CS and LCFS are the weighted
risks for those in that smoking status derived using the risk
equations for predicting the incidence of lung cancer
among never, current, and former smokers respectively in
that calendar year.
Differences due to increases in the risk of smoking
An adjustment to capture the effect of an increased risk due
to smoking after time t0 is performed by incorporating a
term increasing the risk with the number of years smoked
after a speciﬁed calendar year (t0) for continuing smokers
and former smokers. The equation for current smokers
becomes:
b R0
S ¼½ bðt   t0Þ 
It b RS
where
It ¼
1; bðt   t0Þ[1
0; bðt   t0Þ\1
(
€ RS ¼ the lung cancer risk estimated from the CPS 1 risk
equations for continuing smokers, t = current calendar
year, t0 is the designated trigger year and b is a constant.
Since the adjustment is intended to account for an
increase in lung cancer risk over time, the adjustment for
duration of smoking after t0 is only applied in the equation
when it is greater than or equal to 1 and therefore increases
the predicted rate of lung cancer incidence.
The analogous equation for former smokers is:
b R
0
FS ¼½ bðt   t0   tQÞ 
It b RFS
€ RFS ¼ the lung cancer risk estimated from the CPS 1 risk
equations for former smokers, and tQ = the year in which
the former smoker quits smoking.
When both the adjustment for a healthy population bias
and the adjustment for increasing risk with advancing
calendar year are applied, the resulting equation for ade-
nocarcinoma is:
LCSEER ¼ a  ½ ð NS   LCNSÞþð CS   LCCS   b   SCSÞ f
þðFS   LCFS   b   SFSÞ    propAdenog
c
The terms SSC and SFS are the durations of smoking in
years after a speciﬁed calendar year in current and former
smokers, respectively, and b is the same constant for both
groups. Non-linear regression is used to attempt estimation
of the parameters a, c, and b simultaneously; and when the
models do not converge with the effort to simultaneously
estimate a, b, and c, the values for a and c derived from the
previous estimation of a and c in modeling US mortality
data are used to derive b alone, and then that value of b is
used to estimate new values for the parameters a and
c. Estimation of the parameters for different t0 is performed
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estimating one set of a, b, and c for each increment until
the variance, estimated by the mean squared error, was
minimized.
Results
We have previously demonstrated that lung cancer mor-
tality risks observed during the 1960s progressively
underestimate the observed US lung cancer mortality in
White men as calendar year is advanced from 1960 to 2000
(Burns et al., submitted). This underestimate can be
resolved by the introduction of a term for the duration of
smoking after a speciﬁed calendar year suggesting that the
lung cancer risks resulting from smoking may have
increased over time. We now examine whether the same
mortality risk equations derived from the lung cancer
experience in the 1960s predict the changes in birth cohort–
speciﬁc White male incidence of squamous cell and ade-
nocarcinoma of the lung over the calendar year interval
1973–2000.
Risk equations from the CPS I data are applied to
smoking behaviors of 5-year birth cohorts of White men
born from 1915 to 1954 to generate birth cohort–speciﬁc
risks of lung cancer mortality by single calendar year from
1973 to 2000. These overall lung cancer rates are converted
to rates for the histological subtypes of lung cancer by
multiplying them by the fraction of that subtype present in
the SEER data for the years 1973–1975 (0.367 for squa-
mous cell and 0.176 for adenocarcinoma). The predicted
rates are then adjusted to match the observed rates for the
same birth cohorts in the SEER population for the years
1973–2000.
Adjustment for differences between the CPS I
population and the US population
Healthy population selection bias results in the observed
disease rates for an epidemiological study such as the CPS
I being lower than those for the general US population [21].
An adjustment for this underestimation is needed before
examining the question of whether the type-speciﬁc lung
cancer risks of smoking observed during the 1960s have
changed over time. We use a power function to make this
adjustment, and the resulting equation becomes:
Adjusted rate ¼ a   cohort and year specific mortality ð
rate estimate   tumor type proportionÞ
c
The parameters a and c are derived by ﬁtting the
unadjusted predicted rates to the observed incidence for the
histological subtypes in the US population derived from
SEER data. Since survival from lung cancer has changed
only modestly over time, the adjustment for the difference
between mortality and incidence rates is likely to be
reasonably well approximated by the constant in the power
function adjustment.
Incidence of squamous cell carcinoma
and adenocarcinoma assuming no change
in risk over time
For squamous cell carcinomas, the resulting parameter
value for the constant (a) in the power function is 0.66 and
the exponent (c) is 1.23. The fraction of all SEER lung
cancers that are squamous cell during the years 1973–1975
is 0.367.
Figure 1 is an identity plot comparing the birth cohort
and calendar year–speciﬁc estimates of squamous cell
carcinoma adjusted for healthy population bias to the birth
cohort and calendar year–speciﬁc rates for the SEER
population. The adjusted estimates match the SEER data
well, particularly given the relatively simple form of the
adjustment. This suggests that, for squamous cell carci-
noma, there has been little change in the risk of smoking
since the 1960s and that change in smoking behaviors over
time adequately explain changes in incidence rates.
Figure 2 presents comparable data for adjusted esti-
mates of adenocarcinoma of the lung. The same process
was used to estimate incidence rates for adenocarcinoma.
When the parameters for the power function are estimated
by ﬁtting the data, the constant (a) is 3.13 and the exponent
(c) is 0.99. The comparison of adjusted estimates to the
SEER rates in Fig. 2 demonstrates a poor ﬁt with the lower
rates being below the line of identity and the higher rates
Fig. 1 Comparison of SEER squamous cell carcinoma incidence
rates for 5-year birth cohorts of White men by single calendar year
from 1973 to 2000 to the estimates using the CPS I risk equations and
the adjustments described previously, but with no adjustment for
years of smoking after 1950
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where the difference between the estimated and SEER rates
differs systematically by birth cohort.
In order to further examine this pattern, we plotted the
standardized residual error for this comparison by the
calendar year of the observation (Fig. 3). There is a clear
positive trend for the standardized residuals with advancing
calendar year suggesting that a calendar year term would
improve the prediction of incidence rates for adenocarci-
noma. These observations suggest that adenocarcinoma
incidence, in contrast to squamous cell incidence, is not
well predicted by the risk estimates obtained in the 1960s
and that the error in estimation changes as a function of
advancing calendar year.
We also examined the residual error with age. While the
magnitude of the standardized residuals increased with
advancing age, they did not show a directional trend with
age for either squamous cell or adenocarcinoma. Residual
errors for squamous cell plotted against calendar year
showed a very small negative trend (i.e., the opposite
direction of that for adenocarcinoma) with advancing cal-
endar year.
Adjustment for changing risk over time
The strong trend with calendar year for adenocarcinoma in
Fig. 3 and the need to adjust predicted mortality rates for
an increase in the risk of smoking with advancing calendar
year(Burns et al., submitted) led us to add an adjustment to
the estimated adenocarcinoma incidence for the duration of
smoking after speciﬁed calendar years. In order to adjust
for the increasing risk over time suggested by Fig. 3, a term
that multiplies a constant (b) by the duration of smoking
after a speciﬁed calendar year (S) was added to the pre-
dictive equations for current and former smokers. That
equation becomes:
LCSEER ¼ a  ½ ð NS   LCNSÞþð CS   LCCS   b   SCSÞ f
þðFS   LCFS   b   SFSÞ    PropAdenog
c
An effort was made to simultaneously derive the values
for a, b, and c by ﬁtting the estimated rates to the SEER
data, but the solution would not converge in a range of
reasonable values. We then undertook a two-step solution.
The ﬁrst step was to utilize the values for a and c identiﬁed
for the ﬁt of total lung cancer mortality to the US mortality
data (0.78 for a and 1.13 for b) and then derive values for
b. This process was conducted for different calendar years
for starting the measurement of duration in the S term of
the equation above by sequentially deriving values for b for
5-year sequential iterations of speciﬁed calendar years and
examining the goodness of ﬁt for the resulting predicted
incidence. The results of these efforts are presented in
Table 1, and the target year providing the best ﬁt is 1950
with the b term equaling 0.06791.
A second step then utilized the value for the b parameter
for the year 1950 in Table 1 and derived new values for the
a and c parameters by ﬁtting the estimated adenocarcinoma
rates to the SEER adenocarcinoma rates. The resulting
value for a is 1.7593, and the value for c is 0.9243
(MSE = 15.9039, F = 15,435.8). The adjustment for cal-
endar year is only applied when the term multiplying b and
the number of years of smoking after 1950 exceeds one and
therefore only begins to adjust the rates after 1965 and
15 years of duration of smoking. Since the SEER data are
limited to years after 1973 and the risks of adenocarcinoma
are only estimated for individuals above age 40, essentially
Fig. 2 Comparison of SEER adenocarcinoma incidence rates for
5-year birth cohorts of White men by single calendar year from 1973
to 2000 to the estimates using the CPS I Risk equations and the
adjustments described previously, but with no adjustment for years of
smoking after 1950
Fig. 3 Standardized residuals for the difference between SEER and
predicted rates of adenocarcinoma of the lung without adjustment for
calendar year plotted by calendar year
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some extent.
Figure 4 is an identity plot comparing the estimates
adjusted for the duration of smoking after 1950 with the
observed SEER rates. The simple arithmetic adjustment for
the duration of smoking after 1950 results in a reasonably
good estimation of the changes in adenocarcinoma inci-
dence by calendar year and birth cohort even though there
has been a dramatic rise in the proportion of all cancers that
are classiﬁed adenocarcinoma.
Figure 5 presents the standardized residuals for this
comparison plotted against calendar year. The plot of the
residual error against calendar year no longer shows a
systematic trend across calendar year for the difference
between the estimated incidence and the SEER rates
(Fig. 5). Figure 6 presents the predicted adenocarcinoma
incidence rates with the adjustment for duration of smoking
after 1950, the SEER incidence rates for adenocarcinoma
for the years 1973–2000, and the unadjusted estimates for
each of the birth cohorts independently. The predicted rates
approximate the SEER rates well across the calendar years
in each birth cohort. These results suggest that the risk of
cigarette smoking resulting in adenocarcinoma of the lung
has increased substantially over the same time interval
during which there has been substantial changes in the
characteristics of the cigarettes smoked, but the risk of
developing squamous cell carcinoma has remained
unchanged.
We also examined whether adding a term for duration of
smoking after speciﬁed calendar years improved the ﬁt for
squamous cell carcinoma estimates. The introduction of a
term for duration of smoking after 1950 for squamous cell
lung cancer incidence did not substantively improve the ﬁt
of the data.
Discussion
Our analyses demonstrate that changes in birth cohort–
speciﬁc rates of squamous cell carcinoma of the lung over
the last several decades are adequately explained by
changes in smoking behaviors indicating that the risk of
smokers developing squamous cell carcinoma of the lung
has remained unchanged across a period during which
substantial changes in cigarette design were implemented.
In contrast, the risk of smoking for adenocarcinoma has
increased and the prediction of birth cohort–speciﬁc rates is
enhanced by adjusting for an increasing toxicity of the
cigarettes smoked over time. The constant predictive
relationships between smoking behaviors and squamous
cell carcinoma rates over time coupled with an increasing
risk of smoking behaviors for adenocarcinoma suggest that
the increase in adenocarcinoma as a proportion of all lung
Table 1 Values of parameter
b at different starting years for
measuring the duration in the
S term and using the values of
a and c derived from the ﬁt of
the squamous cell data
a Best ﬁt
Adjusted for years smoked after ? 1945 1950
a 1955
b 0.06054 0.06791 0.07798
MSE 8.328782E-8 5.946912E-8 5.974554E-8
F 1,0351.2 14,528.1 14,401.5
Adjusted r
2 0.9843 0.9888 0.9887
AIC -2,688.66 -2,744.24 -2,743.48
Fig. 4 Comparison of SEER adenocarcinoma incidence rates for
5-year birth cohorts of White men by single calendar year from 1973
to 2000 to the estimated rates with adjustment for years of smoking
after 1950
Fig. 5 Standardized residuals for the difference between SEER and
predicted rates of adenocarcinoma of the lung plotted by calendar
year
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cigarettes smoked to cause adenocarcinoma rather than a
shift in tumor type from squamous cell to adenocarcinoma.
While changes in histological classiﬁcation and diag-
nostic techniques may have made modest contribution to
the increase in adenocarcinoma of the lung in the United
States, it is generally recognized that they do not explain
the magnitude of the observed change [5–7]. Shifts in the
age distribution of the population over time can increase
age-adjusted adenocarcinoma rates, but they would not
have a meaningful impact on the birth cohort–speciﬁc rates
we present. Shifts in the socioeconomic distribution of
smokers over time could contribute to an increase in
overall lung cancer death rates, but it is more difﬁcult to
understand how they would explain the shift toward ade-
nocarcinoma. The limited analyses that address this issue
suggest that shifts in the social class of smokers have less
effect on trends in adenocarcinoma than for the other types
of lung cancer [22]. Air pollution, speciﬁcally oxides of
nitrogen, has been suggested as a cause of the rise in
adenocarcinoma of the lung in the United States [23–25],
but the absence of a change in adenocarcinoma rates
among never smokers in the two American Cancer Society
studies [5] conducted more than 20 years apart makes this
hypothesis less likely.
Our results are consistent with other evidence on risk of
adenocarcinoma over time. Early in the examination of the
lung cancer epidemic, the most common lung cancer in men
was squamous cell and the relative risks of smoking for
squamous cell were substantially higher than for adenocar-
cinoma [26, 27]. There was even considerable debate as to
whether adenocarcinoma was associated with cigarette
smoking [28]. With the rise in the frequency of adenocar-
cinoma over time, the relative risks for adenocarcinoma
associated with smoking also increased [5, 29], suggesting
that a new or substantially enhanced risk of developing
adenocarcinoma of the lung was manifesting itself in
smokers. This contrasts with a constant rate of overall lung
cancer, and of adenocarcinoma, among never smokers over
time [5, 11, 12]. When the relative risks of smoking for the
development of adenocarcinoma of the lung were compared
in the two American Cancer Society Cancer Prevention
Studies, the relative risk among smokers for adenocarci-
nomaincreasedfrom4.6formenand1.5forwomeninCPSI
conductedinthe1960sto19.0formenand8.1forwomenin
CPS II conducted in the 1980s [5]. Among never smokers,
the age-adjusted death rates for adenocarcinoma of the lung
were essentially unchanged among never smokers when the
data for CPS I and II were compared [5].
Time trends for age-standardized rates of squamous cell
and adenocarcinoma of the lung are different in the United
States [3, 30]. Age-adjusted rates of squamous cell carci-
noma began to decline among White men in the early to
mid 1980s, whereas rates of adenocarcinoma continued to
Fig. 6 Comparison of predicted and observed birth cohort–speciﬁc rates of adenocarcinoma of the lung for White men by calendar year. The
dashed lines are the unadjusted predicted rates, the solid lines are the adjusted rates, and the points are the values derived from the SEER data
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time trends for adenocarcinoma and squamous cell carci-
noma could be due to a difference in the relationship of age
to squamous cell and adenocarcinoma incidence. Our
analyses address the possibility that the divergence is due to
differences in the relationship with age by demonstrating
that the effect with calendar year is present even when age
and birth cohort are speciﬁed in the analyses and that age-
speciﬁc risksincrease acrosssequentialcohorts.Differences
inadenocarcinomatrendscouldalso bedueto differencesin
thetimecourseofdeclinesinriskfollowingcessationforthe
different tumor types [31]; but if this effect explained our
ﬁndings,theeffectshouldbegreatestatolderageswherethe
prevalence of former smokers is greater. Our results dem-
onstrate a greater effect at younger ages.
There have been substantial changes in cigarette design
and manufacture over to past several decades [32]. Two
principal mechanisms by which changes in cigarette design
can alter the risks of smoking have been suggested and they
may act together [4, 5]. The increase in puff volume and
depth of inhalation observed among smokers of lower tar
yield cigarettes might increase the exposure of lung alve-
olar cells to the carcinogens in smoke. Modeling of smoke
deposition in the lungs of smokers resulting from com-
pensatory changes in smoking behavior suggests that this
effect is likely to occur, but the magnitude of the effect
may not be large enough to explain the observed shift to
adenocarcinoma [33]. A second mechanism is an increase
in the levels of tobacco-speciﬁc nitrosamines in US ciga-
rettes over time [8, 32]. Tobacco-speciﬁc nitrosamines are
organ-speciﬁc carcinogens for adenocarcinoma of the lung
in animals [8], and biomarkers of tobacco-speciﬁc nitros-
amines in the urine predict the risk of lung cancer in
smokers even after controlling for the intensity and dura-
tion of smoking [34, 35]. Levels of tobacco-speciﬁc
nitrosamine biomarkers are also associated with an
increased risk for adenocarcinoma but not other types of
lung cancer [35]. Widespread shift to ﬁltered cigarettes
occurred in the 1950s, and changes in the nitrosamine
levels date at least from the 1960s [32, 36].
Higher levels of tobacco-speciﬁc nitrosamines largely
result from the inclusion of burley tobacco in US style
blended cigarettes, and lower levels of these nitrosamines
are found in the unblended ﬂue-cured tobacco used in
cigarettes sold in the United Kingdom, Canada, and
Australia, with the lowest levels found in Australia [37].
Biomarkers of exposure in smokers conﬁrm these differ-
ences acrosscountries incigarettes translate into differences
in smoker exposures to tobacco-speciﬁc nitrosamines [16].
In England [22] and in Scotland [38], incidence rates for
adenocarcinoma of the lung in men have been increasing
only slightly and squamous cell carcinoma remains the
predominant form of lung cancer in men.
Rates for squamous cell carcinoma are similar for men
in the United States and Canada [2]. However, Canadian
male adenocarcinoma incidence rates remain lower than
those for squamous cell and are well below the adenocar-
cinoma incidence for White men in the United States [2].
Figure 7 presents adenocarcinoma as a percentage of the
four major types of lung cancer for sequential birth cohorts
in the United States and Australia. While there appears to
be a small increase in the proportion of lung cancer i.e.
adenocarcinoma across sequential cohorts in the Australian
data, particularly for recent cohorts of women, the mag-
nitude of the trend and the absolute proportion i.e. adeno-
carcinoma are substantially lower in Australia than in the
United States. Of note, the earliest birth cohorts in the
United States, who would have had the longest exposure to
cigarettes with lower nitrosamine levels, appear to have
proportions of adenocarcinoma similar to the average of all
cohorts in Australia.
Limitations of the analyses
The most substantive limitation of these analyses is that
they lack individual-level data directly linking smoking
behaviors and lung cancer occurrence. As such, they can
only generate hypotheses rather than establish causality.
While the results presented may appear to be an effort to
produce a model of lung cancer risk, our intent was quite
different. Our analyses examine smoking behaviors related
to lung cancer risk and generate simple predictive equa-
tions using those factors with the intent of examining
whether the predictive validity of these factors has changed
over time. Almost certainly additional adjustments could
lead to a better ﬁt of the data, and far more complex risk
models have been published, but our intent was to examine
the effects of calendar year on lung cancer risk due to
smoking rather than to develop the ideal model for pre-
dicting risk.
We also examined the SEER incidence rates for small-
cell and large-cell carcinoma using the same methods. In
general, the analysis of small cell incidence was similar to
that for squamous cell and the analysis of large cell
resembled that of adenocarcinoma, but the smaller number
of observations and variability of the incidence rates by
calendar year within the same birth cohort led to uncer-
tainty as to the appropriate interpretation of these results
and therefore we have not reported them.
Analyses of US lung cancer mortality trends over time
using a similar approach suggest that the risk of smoking
has increased over the past several decades, and the anal-
yses presented in this paper suggest that an increasing risk
of adenocarcinoma makes a substantive contribution to that
increase in risk. If the increases in adenocarcinoma seen in
our analyses are the result of changes in cigarette design
20 Cancer Causes Control (2011) 22:13–22
123over the past several decades, they may have been avoid-
able. Perhaps more important currently, if these changes
can be identiﬁed, they may also be reversible with the Food
and Drug Administration jurisdiction over cigarette-man-
ufacturing processes and they may be avoidable in other
countries through regulatory control of tobacco products
under the WHO Framework Convention on Tobacco
Control.
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